Clearing Factor Inhibitor in Human Atherosclerosis

Abstract

A reduction in heparin-activated clearing factor has been demonstrated in individuals with atherosclerosis or conditions related to it. The recent isolation from normal plasma of an inhibitor to clearing factor suggested that the reduction described might be due to an increased level of inhibitor. This possibility was therefore investigated by determining the inhibitor effect of the plasma of atherosclerotic, diabetic, and nephrotic individuals on the in vitro clearing activity of post-heparin plasma.